SP2509: LSD1 Inhibitor for Acute Myeloid Leukemia Research

2026-01-19

SP2509 stands out as a next-generation LSD1 inhibitor for acute myeloid leukemia research, offering potent, selective disruption of epigenetic repression and enabling robust workflows for apoptosis and differentiation studies. Its synergy with HDAC inhibitors and proven in vivo efficacy position SP2509 as a transformative tool for cancer epigenetics and translational AML research.